近日，一款新获美国食品药品监督管理局（FDA）批准的药物——Revtorpyk™（通用名：Gedatolisib），已被正式纳入美国国家综合癌症网络®（NCCN®）的临床实践指南。该指南针对的是HR+/HER2-局部晚期或转移性乳腺癌患者。这一纳入标志着这款药物在肿瘤治疗领域的权威性认可迈出了关键一步。该消息由Celcuity Inc（CELC）公司对外披露。Revtorpyk™的加入，为特定类型的乳腺癌患者提供了全新的治疗选择与希望。指南的更新，将有助于临床医生在制定个体化治疗方案时，有更多循证依据可供参考。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.